Abdominal Aortic Aneurysm, Without Mention of Rupture, Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture
Conditions
Brief summary
The objective of this clinical investigation is to evaluate, in a controlled setting, the safety and performance of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley InnoMed, Hechingen, Germany) implanted as bridging stent in FEVAR (fenestrated endovascular aortic repair) for complex aortic aneurysms.
Interventions
DEVICEBeGraft Peripheral (BGP) Stent Graft System as bridging stent
BGP Stent Graft System as bridging stent
Sponsors
Marc Bosiers, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Application of BeGraft Peripheral Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient eligible for elective repair of AAA/TAAA extent IV with FEVAR in accordance with the applicable guidelines for vascular interventions (Aneurysm size 5.5cm or aneurysm growth of \>5 mm within 6 months or 1 cm within 1 year). * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient is \>55 years old * Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study * Patient has a projected life-expectancy of at least 12-months * Indication of elective repair of AAA or TAAA with FEVAR in accordance with the applicable guidelines for vascular interventions * Patient needs to have a landing zone in their target vessel of at least 10mm * No early important division branch from the target vessel with risk of coverage * Absence of dissection * Target vessels (renal arteries, superior mesenteric artery and celiac trunk) should have a diameter between 5 and 10 mm * Patient eligible for fenestrated endovascular repair as per IFU of the fenestrated endograft * Angulation of the aorta at the level of the target vessels \<45 degrees * The fenestrated endograft has to be constructed so the fenestrations lie in front of the orifice of the target vessel, and the gap between the fenestration and the orifice of the target vessel should not exceed 10mm.
Exclusion criteria
* Previously implanted endograft * Patients refusing treatment * Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated * Patients with uncorrected bleeding disorders or heparin induced thrombozytopenia * Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding * Any planned surgical intervention/procedure within 30 days of the study procedure * Any patient considered to be hemodynamically unstable at onset of procedure * Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period. * Patients with diffuse distal disease resulting in poor stent outflow * Fresh thrombus formation * Stenosed (\>50%) or occluded target vessel * Angulation between renal artery and aortic wall \<30 degrees * Patients with known hypersensitivity to the stent material (L605) and/or PTFE * Hybrid Approach * Patients with a connective tissue disorder * Patients with mycotic or inflammatory aneurysm * Myocardial infarction or stroke within 3 months prior to the procedure * Patients with an unstable angina pectoris or heart insufficiency NYHA 3 or 4 * Patients with ASA classification 5 or higher * Contraindications against contrast enhanced angiography (a.e. massive hyperthyroidism) * Patients with increased risk of intraoperative rupture * Patients with access vessel which are too tortuous, narrow or any kind of reason that would lead to failure of introducing and advancing an introducer sheath
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy endpoint (1) - Technical success | 1 day post-op | Successful introduction and deployment of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley Innomed, Hechingen, Germany) implanted as bridging stent in FEVAR |
| Efficacy endpoint (2) ) Bridging stent patency at 12 months | 12 months post-op | defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on CT Angio at 12 months |
| Safety endpoint at 12 months | 12 months post-op | Absence of procedure related complications and bridging stent related endoleaks at 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from type I & III endoleaks post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from type I & III endoleaks post procedure and at 6, 12 and 24-months, based on imaging (duplex ultrasound, CT angiography) |
| 30-day mortality | 30 days post-op | — |
| Freedom from stent graft migration post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | defined as freedom from stent graft migration (more than 10 mm) |
| Freedom from AAA diameter increase | 6-, 12, and 24- months post-op | defined as more than 5mm increase in maximum diameter measured at 6- , 12- and 24- months as compared to postop-implantation, based on imaging (duplex ultrasound or CT Angiography) |
| Freedom from aneurysm related secondary endovascular procedures post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from aneurysm related secondary endovascular procedures |
| Bridging stent patency post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Bridging stent patency post-op and at 6-, 12- and 24-months, defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on Duplex ultrasound or CT Angio |
| Freedom from aneurysm related mortality post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from aneurysm related mortality post-procedure |
| Freedom from aneurysm rupture within 12- and 24-months post-implantation | 12, and 24- months post-op | Freedom from aneurysm rupture within 12- and 24-months post-implantation |
| Freedom from any major adverse events post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from any major adverse events post-procedure |
| Health Related Quality of Life scores | 12- and 24-months post-op | Health Related Quality of Life scores at 12- and 24-months post implantation |
| Freedom from conversion to open surgical repair post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from conversion to open surgical repair post-op |
| Freedom from bridging stent related endoleaks post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from bridging stent related endoleaks post-op and at 6-, 12- and 24- months, based on imaging (duplex ultrasound, CT angiography) |
| Freedom from bridging stent related secondary intervention post-procedure | 1 day post-op, 6-, 12, and 24- months post-op | Freedom from bridging stent related secondary intervention post-op, 6-, 12- and 24- months |
Countries
Germany
Outcome results
None listed